A phase II, randomised, double blind, placebo controlled, three way crossover study to assess the bronchodilator effect of RPL554 administered in addition to open label tiotropium in patients with COPD.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs RPL 554 (Primary) ; Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Verona Pharma
- 08 Aug 2017 According to a Verona Pharma media release, dosing in the study has been completed and top-line data is expected in the fourth quarter of 2017.
- 20 Jul 2017 Planned End Date changed from 1 Apr 2017 to 1 Jul 2017.
- 20 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jul 2017.